AMGNNASDAQ— Amgen Inc Price & Analysis

Amgen Inc

HEALTHCARE — DRUG MANUFACTURERS - GENERAL

$437.23

-$6.89-1.55%

Market Cap: $240.11B; Mega Cap
P/E Ratio: 27.47; Fwd: 17.92
EPS (TTM): $16.17
Div. Yield: 2.21%

Technical Summary

RSI (14)62.51Neutral

SMA (50)$395.32Bullish

SMA (200)$354.22Bullish

MACD13.3558Bearish

Bollinger$407.01 – $453.67Mid

Stochastic82.57Overbought

Theo Outlook

Amgen (AMGN) offers a bullish investment thesis supported by a $236.38 billion market capitalization, a trailing P/E ratio of 27.17, diluted EPS of $16.09, and 9.5% year-over-year quarterly revenue growth on $38.095 billion TTM revenue. The company's strong profitability metrics, including a 23% profit margin and 35.5% operating margin, position it favorably in the healthcare sector amid steady demand for its biopharmaceutical products. With a low beta of 0.426 indicating defensive characteristics, AMGN trades at a reasonable valuation relative to its earnings power and dividend yield of 2.21%.

Key catalysts include robust earnings momentum from its latest quarter ending June 2026 and continued pipeline expansion in oncology and inflammation therapies, bolstered by analyst consensus with 4 strong buy and 10 buy ratings alongside a $389.69 target price. Growth drivers encompass market expansion in recombinant DNA-based treatments and potential new product launches that leverage Amgen's established R&D infrastructure, supporting sustained revenue growth above 9% annually.

Risks center on regulatory scrutiny for drug approvals, intensifying competition from biosimilars, and macroeconomic headwinds such as healthcare policy changes or inflation pressures on R&D costs. These are mitigated by Amgen's diversified portfolio, high institutional ownership at 85.1%, and proven ability to navigate patent cliffs through innovation, as evidenced by consistent quarterly earnings growth of 64.9% year-over-year. Analysis generated by HeyTheo AI based on SEC filings, earnings transcripts, and market data.

Analysis generated by HeyTheo AI on Sep 7, 2026.

Company Overview

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology.

Fundamental Snapshot

Revenue: $38.09B
EBITDA: $17.27B
Gross Profit: $27.39B
Operating Margin: 35.5%
Profit Margin: 23.0%
ROE: 91.5%
Book Value: $21.62
Beta: 0.41
52-Wk High: $447.03
52-Wk Low: $262.49
Avg Volume: 1.56M
PEG Ratio: 2.11

Frequently Asked Questions

What is Amgen's business model?

Amgen Inc. operates as a biopharmaceutical company focused on discovering, developing, and manufacturing innovative therapies using recombinant DNA technology for serious illnesses in oncology, inflammation, and cardiovascular areas. It generates revenue primarily through direct sales of branded drugs to healthcare providers and patients worldwide.

What are Amgen's main revenue sources?

Amgen derives the bulk of its $38.095 billion TTM revenue from sales of key biopharmaceutical products, with additional contributions from licensing and collaborations. The company reported 9.5% year-over-year quarterly revenue growth in its latest quarter ending June 2026.

What are Amgen's competitive advantages?

Amgen benefits from deep expertise in molecular biology, a robust pipeline, and high barriers to entry in biologics manufacturing, reflected in its 23% profit margin and 0.915 return on equity. Its low beta of 0.426 and 85.1% institutional ownership further underscore its market position.

What are the key risks for Amgen investors?

Primary risks include regulatory delays in drug approvals, biosimilar competition eroding patents, and macro pressures on healthcare spending. These are offset by Amgen's diversified portfolio, strong R&D, and analyst target price of $389.69 versus its 52-week range of $262.49 to $447.03.

What is Amgen's growth outlook?

Amgen shows solid growth potential with 9.5% revenue growth, 64.9% quarterly earnings growth, and a forward P/E of 18.18, supported by pipeline advancements. Investors should monitor the next earnings date following the June 2026 quarter, with a current P/E of 27.17 and 2.21% dividend yield.